SCHEMBL30130815

SCHEMBL30130815

CC(C)(C)OC(=O)NCc1cccc(-n2ccsc2=N)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GLS O94925 5/20 0.45
▸ BRD4 O60885 3/20 0.44
▸ BRD9 Q9H8M2 1/20 0.43
▸ BAZ2B Q9UIF8 1/20 0.43
▸ BAZ2A Q9UIF9 1/20 0.43
▸ GFER P55789 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ NAMPT P43490 4/20 0.40
▸ CREBBP Q92793 1/20 0.39
▸ KDM4A O75164 1/20 0.39
▸ CCKBR P32239 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23749868 1.00 GLS (0.45) GLSBRD4BRD9BAZ2BBAZ2A
SCHEMBL23727979 0.84 BRD4 (0.41) GLSBRD4BRD9BAZ2BBAZ2A
SCHEMBL30130833 0.83 FAAH (0.38) L3MBTL1HDAC1
SCHEMBL30392423 0.81 BRD4 (0.41) GLSBRD4BRD9BAZ2BBAZ2A
SCHEMBL8318725 0.78 BRD4 (0.48) GLSBRD4BRD9BAZ2BBAZ2A
SCHEMBL30393091 0.77 KCNA5 (0.42) BRD9BAZ2BBAZ2ANAMPTKDM4A
SCHEMBL23749766 0.77 KCNA5 (0.42) BRD9BAZ2BBAZ2ANAMPTKDM4A
SCHEMBL14367982 0.75 PRMT6 (0.56) GLSBRD4GFERHSD17B10L3MBTL1
SCHEMBL4404243 0.75 LMNA (0.54) GLSBRD4GFERHSD17B10L3MBTL1
SCHEMBL23749755 0.73 IGF1R (0.40) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 — — US disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 — — EP disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 — — US disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 GLS 65/4885BRD4 813/4885BRD9 1384/4885
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 GLS 105/4885BRD4 459/4885BRD9 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback